Highlights
The global Oral Cancer Therapeutic market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Oral Cancer Therapeutic is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Oral Cancer Therapeutic is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Oral Cancer Therapeutic in Floor of Mouth Cancer is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Oral Cancer Therapeutic include AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., Endo International Plc, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Mylan NV, Pfizer Inc. and Sanofi, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oral Cancer Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Cancer Therapeutic.
The Oral Cancer Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oral Cancer Therapeutic market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Cancer Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
AstraZeneca Plc
Bristol-Myers Squibb Co.
Eli Lilly and Co.
Endo International Plc
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Mylan NV
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
Segment by Type
Targeted Therapy
Chemotherapy
Segment by Application
Floor of Mouth Cancer
Gum Cancer
Hard Palate Cancer
Inner Cheek Cancer (Buccal Mucosa Cancer)
Lip Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oral Cancer Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oral Cancer Therapeutic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Targeted Therapy
1.2.3 Chemotherapy
1.3 Market by Application
1.3.1 Global Oral Cancer Therapeutic Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Floor of Mouth Cancer
1.3.3 Gum Cancer
1.3.4 Hard Palate Cancer
1.3.5 Inner Cheek Cancer (Buccal Mucosa Cancer)
1.3.6 Lip Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oral Cancer Therapeutic Market Perspective (2018-2029)
2.2 Oral Cancer Therapeutic Growth Trends by Region
2.2.1 Global Oral Cancer Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Oral Cancer Therapeutic Historic Market Size by Region (2018-2023)
2.2.3 Oral Cancer Therapeutic Forecasted Market Size by Region (2024-2029)
2.3 Oral Cancer Therapeutic Market Dynamics
2.3.1 Oral Cancer Therapeutic Industry Trends
2.3.2 Oral Cancer Therapeutic Market Drivers
2.3.3 Oral Cancer Therapeutic Market Challenges
2.3.4 Oral Cancer Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oral Cancer Therapeutic Players by Revenue
3.1.1 Global Top Oral Cancer Therapeutic Players by Revenue (2018-2023)
3.1.2 Global Oral Cancer Therapeutic Revenue Market Share by Players (2018-2023)
3.2 Global Oral Cancer Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oral Cancer Therapeutic Revenue
3.4 Global Oral Cancer Therapeutic Market Concentration Ratio
3.4.1 Global Oral Cancer Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oral Cancer Therapeutic Revenue in 2022
3.5 Oral Cancer Therapeutic Key Players Head office and Area Served
3.6 Key Players Oral Cancer Therapeutic Product Solution and Service
3.7 Date of Enter into Oral Cancer Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oral Cancer Therapeutic Breakdown Data by Type
4.1 Global Oral Cancer Therapeutic Historic Market Size by Type (2018-2023)
4.2 Global Oral Cancer Therapeutic Forecasted Market Size by Type (2024-2029)
5 Oral Cancer Therapeutic Breakdown Data by Application
5.1 Global Oral Cancer Therapeutic Historic Market Size by Application (2018-2023)
5.2 Global Oral Cancer Therapeutic Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Oral Cancer Therapeutic Market Size (2018-2029)
6.2 North America Oral Cancer Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Oral Cancer Therapeutic Market Size by Country (2018-2023)
6.4 North America Oral Cancer Therapeutic Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oral Cancer Therapeutic Market Size (2018-2029)
7.2 Europe Oral Cancer Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Oral Cancer Therapeutic Market Size by Country (2018-2023)
7.4 Europe Oral Cancer Therapeutic Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oral Cancer Therapeutic Market Size (2018-2029)
8.2 Asia-Pacific Oral Cancer Therapeutic Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Oral Cancer Therapeutic Market Size by Region (2018-2023)
8.4 Asia-Pacific Oral Cancer Therapeutic Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oral Cancer Therapeutic Market Size (2018-2029)
9.2 Latin America Oral Cancer Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Oral Cancer Therapeutic Market Size by Country (2018-2023)
9.4 Latin America Oral Cancer Therapeutic Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oral Cancer Therapeutic Market Size (2018-2029)
10.2 Middle East & Africa Oral Cancer Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Oral Cancer Therapeutic Market Size by Country (2018-2023)
10.4 Middle East & Africa Oral Cancer Therapeutic Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Company Detail
11.1.2 AstraZeneca Plc Business Overview
11.1.3 AstraZeneca Plc Oral Cancer Therapeutic Introduction
11.1.4 AstraZeneca Plc Revenue in Oral Cancer Therapeutic Business (2018-2023)
11.1.5 AstraZeneca Plc Recent Development
11.2 Bristol-Myers Squibb Co.
11.2.1 Bristol-Myers Squibb Co. Company Detail
11.2.2 Bristol-Myers Squibb Co. Business Overview
11.2.3 Bristol-Myers Squibb Co. Oral Cancer Therapeutic Introduction
11.2.4 Bristol-Myers Squibb Co. Revenue in Oral Cancer Therapeutic Business (2018-2023)
11.2.5 Bristol-Myers Squibb Co. Recent Development
11.3 Eli Lilly and Co.
11.3.1 Eli Lilly and Co. Company Detail
11.3.2 Eli Lilly and Co. Business Overview
11.3.3 Eli Lilly and Co. Oral Cancer Therapeutic Introduction
11.3.4 Eli Lilly and Co. Revenue in Oral Cancer Therapeutic Business (2018-2023)
11.3.5 Eli Lilly and Co. Recent Development
11.4 Endo International Plc
11.4.1 Endo International Plc Company Detail
11.4.2 Endo International Plc Business Overview
11.4.3 Endo International Plc Oral Cancer Therapeutic Introduction
11.4.4 Endo International Plc Revenue in Oral Cancer Therapeutic Business (2018-2023)
11.4.5 Endo International Plc Recent Development
11.5 F. Hoffmann-La Roche Ltd.
11.5.1 F. Hoffmann-La Roche Ltd. Company Detail
11.5.2 F. Hoffmann-La Roche Ltd. Business Overview
11.5.3 F. Hoffmann-La Roche Ltd. Oral Cancer Therapeutic Introduction
11.5.4 F. Hoffmann-La Roche Ltd. Revenue in Oral Cancer Therapeutic Business (2018-2023)
11.5.5 F. Hoffmann-La Roche Ltd. Recent Development
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Detail
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Oral Cancer Therapeutic Introduction
11.6.4 Merck & Co., Inc. Revenue in Oral Cancer Therapeutic Business (2018-2023)
11.6.5 Merck & Co., Inc. Recent Development
11.7 Mylan NV
11.7.1 Mylan NV Company Detail
11.7.2 Mylan NV Business Overview
11.7.3 Mylan NV Oral Cancer Therapeutic Introduction
11.7.4 Mylan NV Revenue in Oral Cancer Therapeutic Business (2018-2023)
11.7.5 Mylan NV Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Detail
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Oral Cancer Therapeutic Introduction
11.8.4 Pfizer Inc. Revenue in Oral Cancer Therapeutic Business (2018-2023)
11.8.5 Pfizer Inc. Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Oral Cancer Therapeutic Introduction
11.9.4 Sanofi Revenue in Oral Cancer Therapeutic Business (2018-2023)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Oral Cancer Therapeutic Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Oral Cancer Therapeutic Business (2018-2023)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
AstraZeneca Plc
Bristol-Myers Squibb Co.
Eli Lilly and Co.
Endo International Plc
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Mylan NV
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
*If Applicable.